Oruka Therapeutics, Inc. Proceeds from Issuance of Private Placement
Oruka Therapeutics, Inc. (ORKA) reported Proceeds from Issuance of Private Placement of $188.68 million for the 11-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2025-03-06
- 2024-12-31: Proceeds from Issuance of Private Placement 11 month $188.68M.
- 2024-09-30: Proceeds from Issuance of Private Placement 8 month $189.09M.
- 2012-06-30: Proceeds from Issuance of Private Placement 6 month $950.00K.
| Period end | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 8 month | Proceeds from Issuance of Private Placement 11 month |
|---|---|---|---|
| 2024-12-31 | $188.68M 10-K · filed 2025-03-06 | ||
| 2024-09-30 | $189.09M 10-Q · filed 2024-11-13 | ||
| 2012-06-30 | $950.00K 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |